The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.
Two major shareholders in BMS - Wellington Management and Starboard Value - said they would not support the deal and saw it as poorly thought out.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The California-based drugmaker plans to use the money to advance its investigational drugs with MOAs based on immune system responses.